P2.03-032 Efficacy and Safety of Osimertinib as Third-Line or Later Therapy for T790M-Positive Advanced Non-Small Cell Lung Cancer

Autor:	Shuta Yamauchi, Y. Sasahara, K. Yamanaka, R. Imase, H. Majima, T. Hara, S. Endo, Yasuto Jin, A. Kobayashi, T. Ozawa, Y. Sakakibara, K. Yamazaki, O. Matsubara, T. Shinmura, Hiroyuki Shimada
Rok vydání:	2017
Předmět:	Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty business.industry medicine.disease T790M Third line Internal medicine medicine Osimertinib Non small cell Lung cancer business
Zdroj:	Journal of Thoracic Oncology. 12:S2139-S2140
ISSN:	1556-0864
DOI:	10.1016/j.jtho.2017.09.1283
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::03aa7070886d8ab994585518291a6e84 https://doi.org/10.1016/j.jtho.2017.09.1283 Zobrazit plný text záznamu